Literature DB >> 10885973

Phosphodiesterases: the journey towards therapeutics.

T J Torphy1, C Page.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10885973     DOI： 10.1016/s0165-6147(00)01478-4

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


× No keyword cloud information.
  9 in total

1.  Characterization of a catalytic ligand bridging metal ions in phosphodiesterases 4 and 5 by molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.

Authors:  Ying Xiong; Hai-Ting Lu; Yongjian Li; Guang-Fu Yang; Chang-Guo Zhan
Journal:  Biophys J       Date:  2006-09-01       Impact factor: 4.033

2.  Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects.

Authors:  L J Landells; C M Szilagy; N A Jones; K H Banner; J M Allen; A Doherty; B J O'Connor; D Spina; C P Page
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

3.  Rolipram inhibits leukocyte-endothelial cell interactions in vivo through P- and E-selectin downregulation.

Authors:  María-Jesús Sanz; Angeles Alvarez; Laura Piqueras; Miguel Cerdá; Andrew C Issekutz; Roy R Lobb; Julio Cortijo; Esteban J Morcillo
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

4.  Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers.

Authors:  Donna Donigi Gale; Linda J Landells; Domenico Spina; Alan J Miller; Kate Smith; Terry Nichols; Yakov Rotshteyn; Alfred Tonelli; Peter Lacouture; Ronald M Burch; Clive P Page; Brian J O'Connor
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

Review 5.  Therapy for chronic obstructive pulmonary disease in the 21st century.

Authors:  Louise E Donnelly; Duncan F Rogers
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Human PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary change.

Authors:  Kirsty F Mackenzie; Emma C Topping; Bozena Bugaj-Gaweda; Chengjun Deng; York-Fong Cheung; Aileen E Olsen; Cecil R Stockard; Lisa High Mitchell; George S Baillie; William E Grizzle; Michael De Vivo; Miles D Houslay; Daguang Wang; Graeme B Bolger
Journal:  Biochem J       Date:  2008-04-15       Impact factor: 3.857

7.  Regulation of T-cell activation by phosphodiesterase 4B2 requires its dynamic redistribution during immunological synapse formation.

Authors:  Jacqueline Arp; Mark G Kirchhof; Miren L Baroja; Steven H Nazarian; Thu A Chau; Craig A Strathdee; Eric H Ball; Joaquín Madrenas
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

Review 8.  What have transgenic and knockout animals taught us about respiratory disease?

Authors:  Y R Vasquez; D Spina
Journal:  Respir Res       Date:  2000-08-03

Review 9.  Treating COPD with PDE 4 inhibitors.

Authors:  William M Brown
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.